France Strengthens Medical Device Vigilance: What ANSM's Latest Guidance Means for Manufacturers

What's Changed?

In July 2026, France's National Agency for the Safety of Medicines and Health Products (ANSM) reinforced its expectations regarding medical device vigilance and post-market surveillance, publishing updated guidance to help manufacturers, importers, and economic operators comply with the European Union Medical Device Regulation (EU MDR).

The updated guidance highlights manufacturers' responsibilities for reporting serious incidents, monitoring device performance throughout the product lifecycle, identifying safety trends, and implementing corrective actions when necessary. It also reinforces the importance of maintaining effective post-market surveillance systems to support ongoing regulatory compliance and protect public health.

These updates align with the broader objectives of the EU MDR, which places increased emphasis on continuous monitoring of medical devices after they have been placed on the market.

Why This Change Matters

Medical device compliance does not end once a product receives market approval.

Regulators across Europe are placing greater emphasis on post-market surveillance, recognising that continuous monitoring is essential for identifying emerging safety issues, improving product performance, and protecting patients.

For manufacturers marketing medical devices in France and across the European Union, strong vigilance systems are becoming an increasingly important element of regulatory compliance.

Who Needs to Pay Attention?

This regulatory update is particularly relevant for:

✔ Medical device manufacturers

✔ EU Authorised Representatives

✔ Importers and distributors

✔ Regulatory affairs professionals

✔ Quality and compliance teams

✔ Companies placing medical devices on the French or wider EU market

Organisations should review whether their vigilance systems are capable of meeting evolving regulatory expectations.

What Companies Should Do Next

1. Review Vigilance Procedures

Ensure internal procedures clearly define how serious incidents, field safety corrective actions, and trend reports are identified, documented, and submitted.

2. Strengthen Post-Market Surveillance Systems

Evaluate whether post-market surveillance plans effectively capture product performance and support timely regulatory reporting.

3. Train Cross-Functional Teams

Regulatory, quality, clinical, and customer service teams should understand their respective roles in identifying and escalating potential safety issues.

4. Monitor Future ANSM and EU MDR Guidance

Manufacturers should continue monitoring updates from ANSM and the European Commission to ensure ongoing compliance with evolving vigilance requirements.

ARQon Insight

Post-market surveillance is no longer simply a regulatory obligation—it has become a strategic component of product lifecycle management.

Organisations with mature vigilance systems are better equipped to identify risks early, respond efficiently to safety concerns, and maintain regulatory confidence across multiple jurisdictions.

As regulators continue to strengthen oversight, proactive vigilance practices will become an increasingly important competitive advantage.

Global Regulatory Trend

France's latest vigilance guidance reflects a worldwide shift toward stronger post-market oversight.

Regulatory authorities, including the FDA, Health Canada, Australia's TGA, and the UK's MHRA, are all placing greater emphasis on real-world evidence, continuous monitoring, traceability, and timely incident reporting.

Manufacturers operating globally should view post-market surveillance as an integral part of their international regulatory strategy rather than a country-specific requirement.

Key Takeaway

ANSM's updated guidance reinforces the growing importance of effective vigilance and post-market surveillance under the EU MDR.

Manufacturers should take this opportunity to review internal reporting processes, strengthen quality systems, and ensure they are prepared to meet evolving regulatory expectations throughout the product lifecycle.

How ARQon Can Support

ARQon supports healthcare and life sciences companies with:

• Regulatory intelligence and monitoring

• EU MDR compliance support

• Post-market surveillance strategy

• Vigilance reporting guidance

• Medical device regulatory consulting

• Global market access planning

  
  

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.